StarGen (SAR422459) / Oxford Biomedica 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   55 News 
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Journal:  Bioethanol production from sorghum grain with Zymomonas mobilis: Increasing the yield and quality of raw distillates. (Pubmed Central) -  May 5, 2023   
    Trial completion date: Aug 2034 --> Aug 2033 | Trial primary completion date: Aug 2034 --> Aug 2033 The study emphasizes the great potential of bioethanol production from sorghum with Z. mobilis using granular starch hydrolyzing enzyme Stargen 002, which leads to reduce water and energy consumption, especially when energy sources are strongly related to global climate change.
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Journal:  Structural and spectral properties of generative models for synthetic multilayer air transportation networks. (Pubmed Central) -  Dec 1, 2021   
    Besides a thorough study of the topological aspects of the ATNs created by the three models, our major contribution lays on an unprecedented investigation of their spectral characteristics based on Random Matrix Theory and on their resilience analysis based on both site and bond percolation approaches. Results have shown that ANGEL outperforms STARGEN and BINBALL to better capture the complexity of real-world ATNs by featuring the unique properties of building a multiplex ATN layer by layer and of replicating layers with point-to-point structures alongside hub-spoke formations.
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Trial completion date, Trial primary completion date:  Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) -  Aug 11, 2020   
    P1/2,  N=27, Active, not recruiting, 
    Results have shown that ANGEL outperforms STARGEN and BINBALL to better capture the complexity of real-world ATNs by featuring the unique properties of building a multiplex ATN layer by layer and of replicating layers with point-to-point structures alongside hub-spoke formations. Trial completion date: Aug 2033 --> Aug 2034 | Trial primary completion date: Aug 2033 --> Aug 2034
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Enrollment change:  Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) -  Apr 22, 2020   
    P1/2,  N=27, Active, not recruiting, 
    This research demonstrates that rice and sweet potato waste are low-cost feedstocks for PHAs production, paving the way for the processing of other starchy materials into bioplastics. N=46 --> 27
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Enrollment closed:  Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) -  Oct 3, 2019   
    P1/2,  N=46, Active, not recruiting, 
    This study proposes a biorefining strategy that supports the generation of a value-added co-product, starch concentrate, while significantly reducing the enzyme requirements for bioethanol production. Enrolling by invitation --> Active, not recruiting
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Enrollment change, Trial termination:  Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration (clinicaltrials.gov) -  Sep 26, 2019   
    P1/2,  N=27, Terminated, 
    N=41 --> 27 | Recruiting --> Terminated; Study stopped not for safety reasons. Due to review of clinical development plans and priorities, Sponsor decided to stop development of the product.
  • ||||||||||  StarGen (SAR422459) / Sanofi
    Journal:  Consolidated bioprocessing of raw starch with Saccharomyces cerevisiae strains expressing fungal alpha-amylase and glucoamylase combinations. (Pubmed Central) -  May 17, 2019   
    When ateA was co-expressed with the previously reported Aspergillus tubingensis glucoamylase gene (glaA), the amylolytic S. cerevisiae Y294[AteA-GlaA] strain produced 45.77 g l-1 ethanol after 6 days. Ethanol production by this strain was improved with the addition of either 2.83 μl STARGENTM 002 (54.54 g l-1 ethanol and 70.44% carbon conversion) or 20 μl commercial glucoamylase from Sigma-Aldrich (73.80 g l-1 ethanol and 90.19% carbon conversion) This is the first report of an engineered yeast strain that can replace up to 90% of the enzymes required for raw starch hydrolysis, and thus contributes to the realisation of a CBP yeast for starch-based biofuel production.
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Trial completion date, Trial primary completion date:  Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration (clinicaltrials.gov) -  Apr 20, 2019   
    P1/2,  N=41, Recruiting, 
    Ethanol production by this strain was improved with the addition of either 2.83 μl STARGENTM 002 (54.54 g l-1 ethanol and 70.44% carbon conversion) or 20 μl commercial glucoamylase from Sigma-Aldrich (73.80 g l-1 ethanol and 90.19% carbon conversion) This is the first report of an engineered yeast strain that can replace up to 90% of the enzymes required for raw starch hydrolysis, and thus contributes to the realisation of a CBP yeast for starch-based biofuel production. Trial completion date: Feb 2020 --> Jun 2019 | Trial primary completion date: Feb 2020 --> Jun 2019
  • ||||||||||  StarGen (SAR422459) / Oxford Biomedica
    Enrollment status, Trial completion date, Trial primary completion date:  Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) -  Apr 20, 2019   
    P1/2,  N=46, Enrolling by invitation, 
    Trial completion date: Feb 2020 --> Jun 2019 | Trial primary completion date: Feb 2020 --> Jun 2019 Recruiting --> Enrolling by invitation | Trial completion date: Feb 2035 --> Jun 2034 | Trial primary completion date: Feb 2035 --> Jun 2034